Prosecution Insights
Last updated: April 19, 2026

Examiner: NEAGU, IRINA

Tech Center 1600 • Art Units: 1627 1629

This examiner grants 47% of resolved cases

Performance Statistics

46.6%
Allow Rate
-13.4% vs TC avg
748
Total Applications
+58.1%
Interview Lift
1018
Avg Prosecution Days
Based on 696 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
11.7%
§102 Novelty
39.5%
§103 Obviousness
23.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17853537 Pharmaceutical Compositions Comprising Alpelisib Final Rejection Novartis AG
18599953 EFFICIENT STABILIZER IN CONTROLLING SELF ACCELERATED DECOMPOSITION TEMPERATURE OF PEROXYCARBOXYLIC ACID COMPOSITIONS WITH MINERAL ACIDS Non-Final OA ECOLAB USA INC.
18560520 SUBSTITUTED HETEROCYCLIC COMPOUNDS Non-Final OA BRISTOL-MYERS SQUIBB COMPANY
17781297 Treatment or Prevention of Ischaemic Stroke Reperfusion Injury Non-Final OA Cambridge Enterprise Limited
18001889 A NUTRITIONAL COMPOSITION COMPRISING 3-HYDROXYBUTYRIC ACID TO IMPROVE THE GASTROINTESTINAL BARRIER Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
17773257 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTION Non-Final OA UNIVERSITY OF SOUTH FLORIDA
18605474 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE Non-Final OA Ramot at Tel-Aviv University Ltd.
18028338 COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS AND ALLEVIATING FATIGUE Final Rejection University of Miami
18737768 ANTIMICROBIAL COMPOSITIONS Non-Final OA Curie Co. Inc.
17438155 TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS Non-Final OA THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
18568031 USE OF MMP INHIBITORS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME Non-Final OA Foresee Pharmaceuticals USA, Inc.
18568043 SAFE USE OF MMP-12 INHIBITOR Non-Final OA Yuhua LI
18275521 AGENT FOR PREVENTING OR IMPROVING PERIPHERAL NEUROPATHY Non-Final OA KOBAYASHI PHARMACEUTICAL CO., LTD.
18490218 STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS Non-Final OA Xeris Pharmaceuticals, Inc.
18555776 METHOD FOR OBTAINING RIFAPENTINE WITH A NEW CRYSTALLINE FORM Non-Final OA INTERQUIM S.A. DE C.V.
18555106 SIRTUIN OR KLOTHO ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENOLYTIC AGENT Non-Final OA WAKUNAGA PHARMACEUTICAL CO., LTD.
18280628 COMPOSITION FOR AMELIORATING INFLAMMATION OF PERIODONTAL TISSUE Non-Final OA Institute of Rheological Function of Food Co., Ltd.
18279379 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor Non-Final OA Provincial Health Services Authority
18360200 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION Final Rejection Cereno Scientific AB
18225093 C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION Non-Final OA Keto Innovations, LLC
18319334 C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION Non-Final OA Keto Innovations, LLC
18254979 SENOTHERAPEUTIC SUBSTANCE Non-Final OA BIONEXA S.R.L
17690680 Methods and Compositions to Inhibit Symptoms Associated with Opioid Withdrawal Final Rejection SEN-JAM PHARMACEUTICAL LLC
18059142 SYSTEMS AND METHODS FOR SUPPLYING NUTRITIONAL SUPPLEMENTS THAT ELIMINATE PERVASIVE ODORS Non-Final OA Zinpro Corporation
16365074 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM Non-Final OA IMBRIA PHARMACEUTICALS, INC.
17772139 COMPOSITION FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISORDERS Non-Final OA Hideaki HARA
17178652 LIQUID ROPINIROLE COMPOSITIONS Non-Final OA Vici Health Sciences LLC
15348149 COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) AS AN ANIMAL FEED ADDITIVE Final Rejection Metabolic Technologies, Inc.
16881375 DOSING METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS Final Rejection Intact Therapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month